<SEC-DOCUMENT>0000012208-25-000014.txt : 20250304
<SEC-HEADER>0000012208-25-000014.hdr.sgml : 20250304
<ACCEPTANCE-DATETIME>20250304190630
ACCESSION NUMBER:		0000012208-25-000014
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250304
DATE AS OF CHANGE:		20250304

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oncocyte Corp
		CENTRAL INDEX KEY:			0001642380
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				271041563
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89221
		FILM NUMBER:		25707644

	BUSINESS ADDRESS:	
		STREET 1:		15 CUSHING
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		949-409-7600

	MAIL ADDRESS:	
		STREET 1:		15 CUSHING
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OncoCyte Corp
		DATE OF NAME CHANGE:	20200213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oncocyte Corp
		DATE OF NAME CHANGE:	20200205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OncoCyte Corp
		DATE OF NAME CHANGE:	20150513

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO-RAD LABORATORIES, INC.
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DRIVE
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000

	MAIL ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DRIVE
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO RAD LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <!-- Generated by Workiva -->
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0000012208</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Shares, No Par Value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>02/10/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001642380</issuerCik>
        <issuerName>Oncocyte Corporation</issuerName>
        <issuerCusip>68235C107</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>15 Cushing</com:street1>
          <com:city>Irvine</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92618</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>BIO-RAD LABORATORIES, INC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2764078.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2764078.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2764078.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.7</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>The number of shares outstanding for purposes of the percentage calculation in row (11) assumes 28,599,285 outstanding Common Shares of the Issuer as of February 10, 2025, as provided by the Issuer to the Reporting Person. The percentage calculation in row (11) is rounded to the nearest tenth of a percent.  The actual percent as reported in item 4(b) is 9.66%</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Oncocyte Corporation</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>15 Cushing, Irvine, CA, 92618</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Bio-Rad Laboratories, Inc. (the "Reporting Person")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1000 Alfred Nobel Drive, Hercules, California  94547</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>2,764,078 Common Shares</amountBeneficiallyOwned>
        <classPercent>9.66</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>2,764,078 Common Shares</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0 Common Shares</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>2,764,078 Common Shares</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0 Common Shares</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Not applicable</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>Not applicable</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>N</notApplicableFlag>
        <identificationAndClassificationOfGroupMembers>Not applicable</identificationAndClassificationOfGroupMembers>
      </item8>
      <item9>
        <notApplicableFlag>N</notApplicableFlag>
        <groupDissolutionNotice>Not applicable</groupDissolutionNotice>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>BIO-RAD LABORATORIES, INC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Courtney C. Enloe</signature>
        <title>Courtney C. Enloe/Executive Vice President, General Counsel and Secretary</title>
        <date>03/04/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
